Method of treatment of primary open-angle glaucoma

FIELD: medicine; ophthalmology.

SUBSTANCE: carbonic anhydrase inhibitor is instilled. One day after medicamentous therapy started. Azopt therapy is combined with vasotonic massage of anterior ciliary arteries (ACA) that is transconjunctiva ACA effect using multiple alternation of their mechanical compression and decompression by vasotonometer.

EFFECT: higher efficiency of treatment of primary open-angle glaucoma and blood flow improvement of eye great vessel.

1 tbl, 1 ex


The invention relates to medicine, namely to ophthalmology.

It is known that deficiency of blood supply to the eye is one of the pathogenic stages of glaucoma process (Bunin YA et al., 1995). On the contrary, improve blood circulation of the eyes leads to stabilization of glaucoma with the positive dynamics of visual functions. To achieve this goal are vasoreconstructive surgery or conservative methods of influence on the blood flow. Last more popular and widespread because of its non invasiveness, however, are fairly standard, in particular with almost mandatory appointment of both General and local vasodilators without regard to the status of regional blood flow (Krasnov, M.M., 1989). For glaucomatous eyes before assigning vasodilators registration status of the local blood supply is unthinkable without pairing it with the state of the IOP. The interconnectedness and interdependence of hemodynamics and hydrodynamics of the eye is determined by the term "perfusion"whose status is assessed by perfusion pressure (PP) (Lobstein, A., Herr F., 1966). Calculation formula for PD has the following form:


where Rp ophth- perfusion pressure of the eye,

Pmophth- the average dynamic pressure in the ophthalmic artery,

Pioand the true intraocular pressure (IOP).

The described positive effect, confirmed ophthalmodynamometer data and manifested in the increase in perfusion pressure, the decrease in the absolute number of livestock in the field of view in the treatment of patients with open-angle glaucoma vasodilators (beksinski P.P., 2000). However, the impact of systemic vasodilators in the peripheral vessels, such as vessels of the eye, when the pressure-generating vessel causes the weakening of perfusion, which exacerbates the shortage of blood flow. The purpose of vasoconstrictors in local actions that could increase the pressure generating blood vessels in glaucoma is undesirable, first, because almost all of them (for example, adrenaline, mezaton, phenylephrine) have midriatichesky action, and secondly, even when the local application they affect the blood system, which is undesirable when often related primary open-angle glaucoma senile arteriosclerosis and hypertension.

As the closest analogue of our proposed method, we chose a method of treatment of open-angle glaucoma using installationname application of the inhibitor carbonhydrate - azopt (Petrevski A.V. et al., 2002). This drug in accordance with the mechanism of its action reduces the secretion of intraocular fluid, ormalized IOP and thereby increases perfusion pressure (see formula 1). However, it would be desirable to strengthen this influence of azopt on perfusion pressure through activation of the blood flow in the power structures of the eye blood vessels (see formula 1).

In connection with the foregoing features a method of treating primary open-angle glaucoma, consisting in a complex application of local anti-hypertensive medication and local non-drug vasotropic treatments.

Increased blood flow in the feeding eye vessels proposed to be undertaken by non-medical effects on the main blood vessels of the eye - anterior ciliary artery (OCA), which for the anterior eye segment (PSG) perform the role of major blood vessels (Hayreh SS, W.E. Scott, 1978). This effect is vazotonicheskih massage, representing the alternating compression and decompression of the OCA. Massage causes an additional inflow of blood flowing in such departments of the eye, as the ciliary body, the iris, the drainage area. During the development of the methodological aspects of Westonaria in the OCA was installed rise of pressure in these vessels by 50-100% when consistently performed with a small interval between them 3-4x dimensions, i.e. almost vazotonicheskih massage (Petrevski AV, Gundogan I.A., 1994). Simultaneously, it was observed biomicroscopic expressed local hyperemia noticeable expansion of the artery, exposed Westonaria. Thus, temporary occlusion of the vessel caused the development of reactive Hyper in it, and after that there was hyperperfusion structur PSG krovosnabjaemah subjected to massage the OCA. When this blood flow is restored to the off from it due to hypotension in the OCA fragments capillary level of the microvasculature, which was confirmed data biomicroscopy bulbar conjunctiva and limbus, where during vazotonicheskih massage intensified blood flow in the capillary bed and opened "new" capillaries.

Identification of the vessel for vazotonicheskih massage in the proposed method is not difficult and requires no special tests, because episcleral location OCA easily accessible biomicroscopic imaging and various effects, including compression. This anatomical and functional feature allows you to easily terminate or repeat the procedure.

Pathogenetically data selection of vessels for vazotonicheskih massage due to the fact that PSG are 2 important structure is the target of glaucoma process: the ciliary body, secreting intraocular fluid, and drainage area, providing the outflow. From literature data it is known that hemochromatosis disorders in primary open-angle glaucoma is chinautla it in PSG, and the deficit of blood supply leads to the development of degenerative processes in the corneoscleral trabecular, reducing the outflow chamber moisture (Larina ST, 1977; Fedorov, S., 1981). One of the quantitative evidence of inadequate blood supply in PSG is hypotension in the OCA (Petrevski A.V. et al., 2004).

An example of the proposed method. After the examination, including tonography, computerized static perimetry and Westonaria in the OCA with the calculation of perfusion pressure in the PSG by a known method (Petrevski A.V. et al., 2004), the patient was administered instillation of azopt 1 or 2 times a day. A day after the beginning of drug treatment was started daily vazotonicheskih massage, the average duration of a single session which was 5 minutes. Before performing the exposure was carried out epibulbar anesthesia using anesthetic (dikain or inocian). Vazotonicheskih massage was transconjunctival impact in the projection of the tendon attachment of direct muscles, and also in the projection of the vessel, reaching episcleral to emissary along the length thereof, through repeated alternation of mechanical compression and ascend, the Deco. Massage the OCA was carried out using the device, structurally mimic the working part of Wattenmeer our modification (Gundogan I.A., Petrevski A. is., 1997) and represents a metal rod-holder, curved at an angle of 150° and rigidly connected by means of a metal bezel with a microlens made of organic glass, which is in the geometric form of a cylinder of base diameter 5 mm and height 1 mm (innovations, Volga No. 21 from 20.10.03). Massage in the projection of direct tendon of the muscle was carried out by the flat part of the glass sticks laying ointment. Was massaged mainly the upper and lower trunk OCA. When well-marked lateral and medial branches of the massage was exposed and they. The pressure in the OCA was additionally measured before each subsequent procedure.

The treatment was performed in 19 patients with primary open angle glaucoma with normal intraocular pressure (up to 27 mm Hg)treated with azopt as monotherapy once or twice a day.

Treatment consisted of 10 sessions vazotonicheskih massage on the background of receipt of azopt. Upon completion of the course of treatment was performed control tests (tonography, perimetry, Westonaria in the OCA). Comparative data before and after treatment are given in the table.

Hydrodynamic, hemodynamic and functional results of complex treatment in patients with primary drytooling glaucoma, M±m
IndicatorsBefore the treatmentAfter the treatment
IOP, mm Hg23,6±2,515,2±1,9
The pressure in the OCA, mm Hg62,74±3,3868,52±2,84
Perfusion pressure, mm Hg41,30±3,152,0±1,80
The number of cattle absolute17±2,56±0,4

At the end of treatment was achieved correction of hypotension in the OCA and hypogeophis in PSG (table). Positive dynamics in the changes field of view in the form of reducing the absolute number of animals. Pathogenetic orientation, simplicity and security of the proposed method allow for repeated courses of treatment and to achieve stabilization of the glaucomatous process in patients with primary open-angle glaucoma.


1. Beksinski P.P. Effect of conservative therapy and surgical treatment on regional hemodynamics in eyes with primary open-angle glaucoma: author. Diss. Kida. the honey. Sciences. - M., 2000. - 20 S.

2. Bunin YA, Fly A.I., kolomoitseva H. Perfusion pressure in the blood vessels of the eye in patients with open-angle glaucoma.//Vestn. of ophthalmology. - 1995. - T, No. 1. - P.28-31.

3. Gundogan I.A., Petrevski Aviprocessortrial Wattenmeer for measuring the pressure in the anterior ciliary vessels.//The manuscript, Dept. in GCNM. No. 25.402. - M., 1997. - 4 S.

4. Krasnov, M.M. analysis of the characteristics of ocular hemodynamics and therapeutic effect on her glaucoma and blood circulation deficiency.//Journal of ophthalmology. - 1989. No. 6. - P.36-43.

5. Larina ST Morphology of the blood vessels of the sclera for glaucoma./Physiology and pathology of intraocular pressure: proceedings of the Moscow State. the honey. in-TA them. N.I.Pirogov. - M., 1977. - P.35-38.

6. Petrevski AV, Gundogan I. Methodological aspects of Westonaria in episcleral vessels.//Abstracts of the 49th scientific session of the Volgograd honey. Academy. - Volgograd, 1994. - P.39-40.

7. Petrevski AV, Gundogan I.A., Mansur I.D. State perfusion of the anterior segment of the eye in patients with primary open-angle glaucoma.//Glaucoma. - 2004. No. 1 - P.18-23.

8. Petrevski AV, Ballin SV, ALEXANDER Gushchin, Mansur I.D. clinical Experience of azopt in the treatment of primary open-angle glaucoma.//Modern methods of treatment in ophthalmology: Sborn. the scientific. articles. - Nalchik, 2002. - S-99.

9. Fedorov SN. The pathogenesis of primary open-angle glaucoma.//Issues of pathogenesis and treatment of glaucoma: Sborn. the scientific. proceedings of the IRI. - M., 1981. - P.3-7.

10. Hayreh SS, Scott W.E. iris Fluorescein angiography. I. Normal pattern//Arch. Ophthalmol. - 1978. - Vol.96, No. 8. - P.1383-1389.

11. Hayreh SS, Scott W.E. iris Fluorescein angiography. II. Disturbances in iris circulation following strabismus operation on various recti.//Arch. Ophthalmol. - 1978. - Vol.96, No.. - P.1390-1400.

12. Lobstein, A., Herr F. L ophthalmodynamometrie dans le glaucoma.//Ann. Oculist. - 1966. - Vol.199. - P.38-69.

A method of treating primary open-angle glaucoma by instillation inhibitor carbohydrase of azopt, characterized in that through the day after the start of medication in the background get azopt exercise vazotonicheskih massage anterior ciliary arteries (OCA) - transconjunctival impact on the OCA through repeated alternation of mechanical compression and decompression using Wattenmeer.


Same patents:

FIELD: medicine.

SUBSTANCE: Invention relates to ophthalmology, and can be used for treatment of glaucoma optic neuropathy. Dibicor in dose 0.5g two times a day during 1 month, then cortexin and retinalamin in dose 10 mg intramuscular every second day during 20 days are prescribed. Method allows to increase electrophysiological activity of visual analyser in patients with primary open-angular glaucoma due to pathogenically grounded successive application of said medications, on the first stage of treatment intracellular exchange in ganglionar cells of retina improves, then synaptic lesions and transmission of nerve impulse from retina to cortical centre of visual analyser are activated.

EFFECT: increase of electrophysiological activity of visual analyser in patients with primary open-angular glaucoma.

1 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: method involves introducing anecortavi acetas at a dose of 3-15 mg in posterior juxtascleral injection or injection into vitreous body or as implant.

EFFECT: enhanced effectiveness of treatment.

18 cl, 5 dwg, 4 tbl

FIELD: organic chemistry, medicine, biochemistry pharmacy.

SUBSTANCE: invention relates to using the known 2-phenyl-substituted imidazotriazinone of the formula (I): (vardenafil) possessing improved properties as compared with other known inhibitors of phosphodiesterase-5 (PDE-5), such as sildenafil and tadalafil. Proposed compound is used for preparing drugs used in treatment of cardiac insufficiency.

EFFECT: valuable medicinal and biochemical properties of compound.

1 tbl

FIELD: medicine, ophthalmology, chemical-pharmaceutical industry, pharmacy.

SUBSTANCE: invention relates to design of ophthalmological agents of broad spectrum based on vegetable components, vitamins and trace elements. Agent for treatment of eye diseases comprises bilberry berries of sublimation drying, dihydroquercetin, beta-carotene, selexen, lutein, vitamins B1, B2, B6, B12 and zinc. Agent shows the effect of broad spectrum and possesses regenerating, tonic and regenerative effect being without irritating, allergizing, inflammatory and other undesirable effects, and excluding mechanical contact with eye surface.

EFFECT: valuable medicinal properties of agent.

5 cl

FIELD: medicine.

SUBSTANCE: method involves carrying out tonometry, patient examination in slit lamp light, determining filtration cushion size and relief, carrying out test with sterile air introduced under conjunctiva in operation zone in combination with glycocorticosteroid preparation. Filtration cushion height increasing and air entering the anterior chamber, diuretic drugs are prescribed and preparations inhibiting intraocular fluid secretion. Filtration cushion becoming flat, glycocorticosteroid preparations, enzyme preparations are introduced and antimetabolite is introduced under conjunctiva outside of operation field. Filtration cushion relief being variable and air passes into the anterior chamber, anti-inflammatory therapy, anti-proliferative treatment course, glycocorticosteroid and enzyme preparations are prescribed. Filtration cushion becoming flat, and air does not enter the anterior chamber, gonioscopy is carried out and surgical intervention zones are revised in the cases of open internal fistula and antibiotic of cytostatic activity is to be prescribed. Internal fistula being blocked, laser surgical intervention is carried out. Hypertension being persistent, anti-glaucoma intervention is carried out in another eyeball segment with antibiotic of cytostatic activity being applied.

EFFECT: enhanced effectiveness of treatment selection.

FIELD: organic chemistry, medicine, ophthalmology, pharmacy.

SUBSTANCE: invention relates to novel derivatives of benzo[g]quinoline of the formula (I): as a free base or acid-additive salt used in treatment of glaucoma and myopia, and to a method for their synthesis and a pharmaceutical composition. In compound of the formula (I) each A and B means hydrogen atom (H); X means -CH2; Y means sulfur atom (S); R1 means H or (C1-C4)-alkyl wherein this compound can be in form of a free base or acid-additive salt. Method for synthesis of compound of the formula (I) by claim 1 or its salt involves the conversion step of alkoxy-group in compound of the formula (II): wherein A, B, X, Y and R1 have values given in claim 1; R3 means (C1-C4)-alkyl to hydroxy-group, and conversion of synthesized compounds of the formula (I) to free base or its acid-additive salt.

EFFECT: improved method of synthesis, valuable medicinal properties of compounds and pharmaceutical composition.

7 cl, 1 ex

FIELD: medicine, ophthalmology.

SUBSTANCE: method involves administration of chitosan sponge with square up to 2 cm2 into sub-Tenon's space wherein chitosan sponge shows the deacetylation degree 98%, its molecular mass is 1000 kDa and it comprises 2.8 x 10-9 g of hyaluronic acid, 27.8 x 10-8 g of chondroitinsulfuric acid, 3.06 x 10-11 g of cattle serum growth factor and 7 x 10-9 g of heparin per 1 mm2 of chitosan sponge. Method provides stabilizing visual function, to improving vision and expanding vision field based on enhancing sensitivity of optic nerve as result of blood stream enhancing. Invention can be used in treatment of progressing glaucoma with non-stabilizing functions.

EFFECT: improved method of treatment.

1 tbl, 1 ex

FIELD: medicine, ophthalmology, medicinal biochemistry.

SUBSTANCE: invention relates to manufacturing ophthalmic composition used for reducing intraocular pressure. Invention proposes using inhibitors of glycogen synthase kinase-3. Proposed composition provides reducing intraocular pressure by increasing intraocular liquid efflux and to prevent loss of retina ganglion cells.

EFFECT: valuable medicinal properties of inhibitors.

19 cl, 6 ex

FIELD: medicine.

SUBSTANCE: method involves introducing Mytomycin C metabolite into eyes where compensated and subcompensated intraocular pressure being achieved as a result of maximum hypotensive therapy application. The preparation is introduced 4 weeks in advance before operation in initial and advanced glaucoma stages and 2-3 weeks in advance in cases gone too far. The dose to be introduced is equal to 0.1 ml with concentration equal to 0.15 mg/ml. Additional Mytomycin C injection of the same volume and concentration of 0.2 mg/ml is introduced after having finished the reparative operation.

EFFECT: enhanced effectiveness of treatment; prolonged intraocular pressure stabilization.

1 tbl

FIELD: medicine, ophthalmology.

SUBSTANCE: method involves administration of the preparation "Ginkor-Fort" in the dose 1 tablet, 2 times per a day for 2 weeks and after one month break the preparation "Diovenor" is administrated in the dose 1 tablet, once per a day for 2 weeks at the constant instillation of the preparation "Ksalatan" in the dose 1 drop, once time before night. Such schedule of the method provides the stable normalization of intraocular pressure based on improvement of venous orbital and cerebral circulation. Invention is designated for medicinal treatment of glaucoma discirculatory variant.

EFFECT: improved method of treatment.

2 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: claimed invention relates to the field of medications, particularly, to pharmaceutical tablet, including tablet base with distributed in it 0.1-10 mg of tamsulosin or its pharmaceutically acceptable salt, hydroxypropyl methyl cellulose in amount from 10 wt % to 90 wt %, and non-obligatory having enterosoluble coating over said base, where said tablet represents tablet with modified release. In addition, invention relates to method of treatment of benign prostate hyperplasia.

EFFECT: producing tamsulosin tablet with reduced dependence on food intake.

31 cl, 6 dwg, 12 tbl, 6 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine and can be used in analytical laboratories for standardisation and quality assurance of medical products. The method involves preparing solutions of defined substance and the standard reference solution. Clear water and 0.1 M sodium hydroxide solution are used as a dissolvent for preparation of a defined solution, nickel chloride being used as the standard reference solution. The method further includes measuring optical density of a defined solution and reference nickel chloride solution using spectrophotometer; calculating results from the formula and entering recalculation factor therein.

EFFECT: increased sensitivity of the analysis and reproducibility of results; reduced toxicity, labour input, and analytical error.

2 ex

FIELD: chemistry.

SUBSTANCE: invention concerns 2-(butyl-1-sulfonylamino)-N-[1(R)-(6-methoxypyridine-3-yl)propyl]benzinamide of the formula (I) , as well as its pharmaceutically acceptable salts, their obtaining and application, particularly in treatment and prevention of atrial arrhythmia types, e.g. atrial fibrillation or atrial flutter. Also, the invention describes a pharmaceutical composition including compound of the formula (I) with anti-arrhythmic effect.

EFFECT: new compound and pharmaceutical composition based there on for treatment and prevention of atrial arrhythmia.

8 cl, 1 tbl, 2 ex

FIELD: medicine; pharmacology.

SUBSTANCE: composition contains 25-600 mg of Acidum lipoicum and 107 to 1011 living cells of the bacteria chosen from a group of bifidobacterium and lactobacillus. The of method consists in peroral introduction of the said composition by a course of, at least 5 days. When tested at adequate models, the proposed group of inventions shows a synergetic effect of peroxidation suppression of blood serum lipids, that, in particular, is expressed in depression of indicators of size of fast flash when inputing ions into medium of divalent iron, rising ability of lipoproteins of high density to suppress Fe2+ stimulating peroxidation of lipids in standard cheniiluminescent system, and also in established for the composition of Acidum lipoicum with bifidobacterium, depression of content of malonic aldehyde in blood serum.

EFFECT: increased efficiency of the composition.

7 cl, 1 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: haemostatic compressing bandage represents appliance, having guide rail with fixed on it one-piece spiked clamping plates (one of them is still, another is moving) and rotating drum with ratchet gear. Between the still plate and cylinder drum, which is fixed on guide rail, armoured belt made of non-hygroscopic air-penetrable material is set with movable hygroscopic swab/bolster. The haemostatic compressing bandage is impregnated with new original haemostatic medicinal composition, including ingredients as follows (by weight): N-(β-oxymethyl)-4,6-dimethyl-dihydropirimidone-2 (xymedone) - 20.0-22.0%, phenylephrine (mesatone) - 2.0-2.5%, decilate - 1.0-1.2%, boric acid - 9.5-10.0%, aqueous 50% glycerol solution.

EFFECT: increase in efficiency of external hemorrhage arresting.

3 cl, 7 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to application of compounds with formula R2=R1-X, where R1 and R2 have 23 to 35 carbon atoms in sum, X represents primary alcohol functional group -CH2OH or carboxyl group -COOH, R1 is saturated linear hydrocarbon chain with 9 carbon atoms, and R2 is linear hydrocarbon chain, which is saturated or unsaturated, including 1 to 4 unsaturated double links.

EFFECT: producing formulations suited for application to hypercholesterolemia therapy and prophylaxis.

3 cl, 4 tbl, 6 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to surgical stomatology and can be used for treatment of chronic periodontitis. For this purpose operative access to teeth roots with root canals which are difficult or impossible to reach, complicated by radicular cyst, is performed. Prepared cavity is processed with constant current of 4-5 mA during 15 minutes through isotonic solution of sodium chloride with trypsinum in ratio 0.1:2 by apparatus "Potok-1". Retrograde filling of root canal is fulfilled with glassionomeric cement "ProRoot". Then it is processed with semi-conductive laser diode, generating pulse light with wave frequency from 0.85 to 0.98 mcm, pulse power 2-4 Watt, pulse duration 40-100 Ns, pulse frequency 1.5-2.0 kHz, magnetic field strength 35 mT during 5 minutes by apparatus "Optodan". After that, it is filled with osteoinducing bioresorbing material "Osteoplast-K" at 2/3 of bone wound, covered with bioresorbing membrane "Paradoncol" and film "Diplen-denta" with metronidasole from oral cavity. The method ensures effective tooth-preserving treatment and reduction of number of post-operative complications due to reliable sterilisation of micro-canals of tooth root and bone wound cavity, obturation, biointegration and angio-osteogenesis, stimulation of osteoreparative process in bone wound, as well as due to preservation of stability and occlusive integration of tooth in tooth arch.

EFFECT: increased effectiveness of tooth-preserving treatment in case of chronic periodontitis and reduction of number of post-operative complications.

4 ex, 1 dwg

FIELD: medicine; stomatology.

SUBSTANCE: tooth extraction is followed by 5-minutes processing of bone cavity with wave guide "Optodan" with the semiconductor laser diode, generating pulse light of wave length within 0.85 to 0.98 microns. Pulse power is 2-4 W, pulse duration is 40-100 nm, and pulse frequency is 1.5-2.0 kHz, magnetic field intensity is 35 mTl. Cavity is processed through miramystine solution; washed with 30% lincomycin hydrochloride solution and 1 % dioxidyn solution taken in ratio 3:1. Then bone wound is filled with bioresorbed osteoplastic material "AlgOss" with size of granules by 0.25, 0.5 and 1 mm depending on bone defect size by 2/3 of volumes. Wound is isolated mouth cavity with film "Diplen-denta" with lincomycin.

EFFECT: method provides bone grafting with minimum postoperative complications owing to creation of depot medicinal agents in wound and stimulations of regenerative processes.

4 ex

FIELD: medicine.

SUBSTANCE: background symptomatic pharmacotherapy and respiratory gymnastics are combined with foam bathes with 30 ml of 1% solution "Biolong" added. Foam is generated by compressor unit through "pearl grid", water volume is 50 l, bath capacity is 200 l, and water temperature is 38-39°C. Procedure duration is 20-25 minutes. Procedures are carried out every day during 5 days, with interval 2 days; total course duration 10-12 bathes.

EFFECT: provides anti-inflammatory, analgesic effects; prolongs remission time.

3 ex

FIELD: veterinary science.

SUBSTANCE: invention proposes an agent comprising, wt.-%: fumaric acid, 2.0-3.5, and montmorillonite clay, the balance. Proposed agent provides correction of metabolism, it acts as a protecting agent against stress, activates processes of aerobic oxidation, normalizes energy supplying in adaptation processes, adsorbs gases, alkaloids, heavy metals and poisons actively. Use of the agent in animal husbandry and poultry farming enhances productivity in average by 9.5% and 7.5% and safety of agricultural animals and poultry by 6.1% and 6.7%, respectively.

EFFECT: valuable properties and enhanced effectiveness of agent.

1 tbl, 2 ex

FIELD: medicine; ophthalmology.

SUBSTANCE: method of intraocular pressure measurement through eyelid is based on static eyelid deformation by support loading with two flanges and simultaneous dynamic eyeball deformation through eyelid with free-falling rod at subsequent measurement of rod time-motion function parameters. Measurement is performed twice with different static eye loadings of support. Dynamic eyeball deformation can also be carried out by counter-balanced rod, thus rod gets speed due to acceleration unit. Besides, acceleration of rod can be due to magnetic field. In case of multiple dynamic eye deformation with increasing eye pressure force at the moment of occurrence of sclera or cornea deformation wave, intraocular pressure value is registered, then increasing dynamic eye deformation is stopped. Device used for intraocular pressure measurement contains eye pressure sensor and rod motion velocity sensor.

EFFECT: application of this group of inventions provides detection of intraocular pressure through eyelid regardless of geometrical and physical characteristics.

13 cl, 4 dwg